Eukarys

Executive Summary

Eukarys is a French biotechnology company that leverages artificial intelligence and machine learning to transform biomanufacturing. Its patented C3P3® technology, an artificial RNA polymerase, dramatically boosts protein production yields in mammalian cell cultures. This innovation addresses a critical bottleneck in producing complex biomedicines, enabling faster, more efficient, and lower-cost manufacturing. Eukarys aims to become a key enabler for the biopharmaceutical industry by providing a platform that enhances the expression of recombinant proteins, including monoclonal antibodies and gene therapies. Founded in 2019 and headquartered in Paris, the company is privately held and has not disclosed funding details. However, its technology holds significant promise for reducing manufacturing costs and increasing accessibility of biologic drugs. The company's early-stage nature and lack of public data introduce uncertainty, but the C3P3 platform could disrupt traditional bioprocessing if successfully commercialized.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement65% success
• H1 2027Partnership with a Major Biopharma Company40% success
• Q2 2026Publication of Proof-of-Concept Data in a Peer-Reviewed Journal70% success